In summary, in our model, CD133+ cells showed the ability to promote the release of the hemopoietic and renoprotective hormone EPO in vivo and abrogated EPO reduction occurring after AKI by stimulating the release of the EPO of both mice and human origin. This evidence concerns the gene PROM1 and acute kidney injury.